Vitalograph Successfully Passes MHRA and FDA Audits

Vitalograph has passed its first routine inspection by The Medicines and Healthcare products Regulatory Agency (MHRA). The Agency reported zero critical findings, zero major findings and few observations. Vitalograph is one of 5% of CROs to pass with this degree of success.

“The results of our MHRA audit in October confirms that our systems and processes...meet the high standards of best practice demanded by this rigorous regulatory environment,” says Vitalograph Clinical Trials Director, Lewis Weidman.

Last year’s FDA audit of the Vitalograph research and manufacturing facility in Ennis, Ireland was also a great success, with zero deficiencies {483's} raised.